Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-03-20
2007-03-20
Tsang, Cecilia J. (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S008100, C424S001690
Reexamination Certificate
active
10299162
ABSTRACT:
A method of treating a patient having heart failure due to LV systolic dysfunction with an LV ejection fraction less than 40%. The method includes the steps of administering to a patient in need thereof, a compound selected from the group consisting of GIP, GIP analogs, GIP derivatives and pharmaceutically-acceptable salts thereof, GLP-1, GLP-1 analogs, GLP-1 derivatives and pharmaceutically-acceptable salts thereof, at a therapeutically effective amount to improve LV function.
REFERENCES:
patent: 6706689 (2004-03-01), Coolidge et al.
patent: 2002/0107206 (2002-08-01), Coolidge et al.
patent: 2002/0146405 (2002-10-01), Coolidge et al.
patent: 2003/0220255 (2003-11-01), Knudsen et al.
patent: 2004/0002454 (2004-01-01), Coolidge et al.
patent: 2004/0180824 (2004-09-01), Knudsen
Richard P. Shannon, Disclosure to Mario Ehlers, (Oct. 17, 2000).
L.A. Nikolaidis et al., “Mechanisms Whereby Rapid Ventricular Pacing Causes LV Dysfunction,” Abstract, (Mar. 21, 2001).
Lazaros A. Nikolaidis, et al., “GLP-1 Improves Myocardial Performance in Conscious Dogs With Pacing Induced Heart Failure,” Abstract, (Mar. 21, 2001).
Lazaros A. Nikolaidis, et al., “Effects of Glucagon-Like Peptide-1 in Patients With Acute Myocardial Infarction and Left Ventricular Dysfunction After Successful Reperfusion,” Circulation, p. 962-965, (Mar. 2, 2004).
Lazaros A. Nikolaidis, et al., “Recombinant Glucagon-Like Peptide-1 Increases Myocardial Glucose Uptake and Improves Left Ventricular Performance in Conscious Dogs With Pacing-Induced Dilated Cardiomyopathy,” Circulation, p. 955-961, (Aug. 24, 2004).
Hiroshi Yamamoto, et al., “Glucagon-Like Peptide-1 Receptor Stimulation Increases Blood Pressure and Heart Rate and Activates Autonomic Regulatory Neurons,” The Journal of Clinical Investigation, vol. 110 (No. 1), p. 43-52, (Jul. 2002).
Martin G. Vila Petroff, et al., “Glucagon-Like Peptide-1 Increases cAMP but Fails to Augment Contraction in Adult Rat Cardiac Myocytes,” Circulation Research, p. 445-452, (Aug. 31, 2001).
Lazaros A. Nikolaidis, et al., “Glucagon-Like Peptide-1 Limits Myocardial Stunning after Brief Coronary Occlusion and Reperfusion in Conscious Canines,” The Journal of Pharmacology and Experimental Therapeutics, vol. 312 (No. 1), p. 1-6, (2005).
Jose M. Barragan, et al., “Interactions of Exendin-(9-39) with the Effects of Glucagon-Like Peptide-1-(7-36) Amide and of Exendin-4 on Arterial Blood Pressure and Heart Rate in Rats,” Regulatory Peptides 67, p. 63-68, (1996).
Jose' Manuel Barragan, et al., “Neural Contribution to the Effect of Glucagon-Like Peptide-1-(7-36) Amide on Arterial Blood Pressure in Rats,” The American Physiological Society, p. E784-E791, (1999).
Ewa Bojanowska, et al., “Effects of Centrally or Systemically Injected Glucagon-Like Peptide-1 (7-36) Amide on Release of Neurohypophysial Hormones and Blood Pressure in the Rat,” Regulatory Peptides 91, p. 75-81, (2000).
J. M. Barragan, et al., “Changes in Arterial Blood Pressure and Heart Rate Induced by Glucagon-Like Peptide-1-(7-36) Amide in Rats,” The American Physiological Society, p. E459-E466, (1994).
Lazaros A. Nikolaidis, et al., “Active Metabolite of GLP-1 Mediates Myocardial Glucose Uptake and Improves Left Ventricular Performance in Conscious Dogs with Dilated Cardiomyopathy,” Abstract, p. 1-34.
L.A. Nikolaidis, et al., “Active Metabolite of GLP-1 Mediates Myocardial Glucose Uptake and Improves Left Ventricular Performance in Conscious Dogs with Dilated Cardiomyopathy,” Entrez PubMed, p. 1-2, (Jul. 25, 2005).
Lazaros A. Nikolaidis, et al., “Active Metabolite of GLP-1 Mediates Increases Myocardial Glucose Uptake and Improves Hemodynamics in Dilated Cardiomyopathy,” Circulation, vol. 110, No. 17, (Oct. 26, 2004).
Lazaros A. Nikolaidis, et al., “Glucagon-Like Peptide-1 (GLP-1) Limits Myocardial Stunning Following Acute Coronary Occlusion and Reperfusion in Conscious Canines,” Abstracts, Journal of the American College of Cardiology, (Mar. 6, 2002).
Lazaros A. Nikolaidis, et al., “Safety and Efficacy of GLP-1 in Acute Myocardial Infarction Association with Left Ventricular Systolic Dysfunction,” Circulation, vol. 106, No. 19, (Nov. 5, 2002).
Lazaros A. Nikolaidis, et al., “Recombinant Glucagon Like Peptide-1 (rGLP-1) Improves Survival in Spontaneously Hypertensive Heart Failure (SHHF) Rats,” Abstracts from Scientific Sessions 2003, Circulation, vol. 108, No. 17, (Oct. 28, 2003).
Indu Poornima, et al., “The Synergistic Effects of Aging and Heart Failure on Myocardial Insulin Signaling in Spontaneously Hypertensive Heart Failure (SHHF) Rats,” Abstracts from Scientific Sessions 2003, Circulation, vol. 108, No. 17, (Oct. 28, 2003).
Elahi Dariush
Shannon Richard P.
Allegheny-Singer Research Institute
Audet Maury
Schwartz Ansel M.
Tsang Cecilia J.
LandOfFree
Method of treating left ventricular dysfunction does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treating left ventricular dysfunction, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating left ventricular dysfunction will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3759721